About johnson & johnson - JNJ
JNJ At a Glance
| Phone | 1-732-524-0400 | Revenue | 85.15B | |
| Industry | Pharmaceuticals: Major | Net Income | 14.17B | |
| Sector | Health Technology | Employees | 131,900 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
JNJ Valuation
| P/E Current | 25.309 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 28.324 |
| Price to Sales Ratio | 4.713 |
| Price to Book Ratio | 5.486 |
| Price to Cash Flow Ratio | 17.609 |
| Enterprise Value to EBITDA | 13.789 |
| Enterprise Value to Sales | 4.801 |
| Total Debt to Enterprise Value | 0.074 |
JNJ Efficiency
| Revenue/Employee | 645,579.985 |
| Income Per Employee | 107,422.29 |
| Receivables Turnover | 5.725 |
| Total Asset Turnover | 0.48 |
JNJ Liquidity
| Current Ratio | 1.156 |
| Quick Ratio | 0.914 |
| Cash Ratio | 0.495 |
JNJ Profitability
| Gross Margin | 68.961 |
| Operating Margin | 26.026 |
| Pretax Margin | 17.688 |
| Net Margin | 16.64 |
| Return on Assets | 7.509 |
| Return on Equity | 18.308 |
| Return on Total Capital | 13.433 |
| Return on Invested Capital | 13.276 |
JNJ Capital Structure
| Total Debt to Total Equity | 44.249 |
| Total Debt to Total Capital | 30.676 |
| Total Debt to Total Assets | 18.162 |
| Long-Term Debt to Equity | 39.231 |
| Long-Term Debt to Total Capital | 27.197 |
Johnson & Johnson in the News
J&J has enough support from claimants for $6.5 billion talc settlement: report
Johnson & Johnson is reportedly nearing enough support to finalize a $6.5 billion settlement for lawsuits related to cancer cases linked to its baby powder and other talc products.
Left-wing activism rampant in corporate shareholder proposal process: report
A Securities and Exchange Commission process for approving shareholder proposals favors a left-wing bent in corporate policies, claims a watchdog, citing audits from 2018-2022.
Pharma giant adds Israel to list of Middle East markets after omission raises questions
Johnson & Johnson has added Israel to its Customer Connect order management website after questions rose over why it was excluded while "Palestine" was not.
Johnson & Johnson proposes to pay $6.5B to settle talc ovarian cancer lawsuits in US
Through a bankruptcy filing of its subsidiary company, J&J will be able to resolve about 99.75% of the pending talc lawsuits against the company and its affiliates in the U.S.
Judge certifies Johnson & Johnson shareholder class action over talc disclosures
A federal judge said Johnson & Johnson shareholders may pursue as a class action their lawsuit accusing the company of concealing how its talc products were contaminated by asbestos.
Coalition calls on Congress to repeal Biden's prescription drug price controls
More than 40 groups have signed onto a letter asking Congress to end the prescription drug price control scheme included in the Inflation Reduction Act.
NJ Democrat-turned-Republican considers challenging scandal-plagued Menendez: 'If I run, I'll beat him'
Rep. Jeff Van Drew, a Cape May Republican and former Democrat, said if he decides to run against Sen. Robert Menendez or for his seat, he will win.
Johnson & Johnson ditching script logo after 130 years
Johnson & Johnson announced that it's ditching the classic cursive script it has used for 130 years in favor of a revamped logo that pays homage to the old design.
Corporate diversity policies may face scrutiny after Supreme Court's affirmative action ruling
The Supreme Court's ruling rejecting the use of affirmative action and consideration of race as a factor in college admissions could prompt challenges to companies' diversity programs.
J&J consumer-health IPO process to kick off key test for moribund new-issue market
J&J’s consumer business makes Tylenol; Band-Aids and other wound-care products; baby-care products such as Johnson’s Baby Shampoo; and skin-care offerings such as Aveeno and Neutrogena.